Melvin D. Reuber v. United States of America (Two Cases.) Melvin D. Reuber v. Food Chemical News (Two Cases.)

750 F.2d 1039, 242 U.S. App. D.C. 370
CourtCourt of Appeals for the D.C. Circuit
DecidedJanuary 23, 1985
Docket82-2376, 82-2414, 83-1536 and 83-1537
StatusPublished
Cited by219 cases

This text of 750 F.2d 1039 (Melvin D. Reuber v. United States of America (Two Cases.) Melvin D. Reuber v. Food Chemical News (Two Cases.)) is published on Counsel Stack Legal Research, covering Court of Appeals for the D.C. Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Melvin D. Reuber v. United States of America (Two Cases.) Melvin D. Reuber v. Food Chemical News (Two Cases.), 750 F.2d 1039, 242 U.S. App. D.C. 370 (D.C. Cir. 1985).

Opinions

WALD, Circuit Judge:

Plaintiff Dr. Melvin D. Reuber, appeals the district court’s dismissal of his Federal Tort Claims Act (FTCA) suit against the United States, and his constitutional tort and common law claims against several federal officials, Litton Industries, Inc. (Litton), Litton Bionetics, Inc. (Bionetics), and numerous employees of Bionetics.1 Reuber’s suits are grounded in the issuance and dissemination of a letter of reprimand from his employer, Bionetics, charging that he mischaracterized personal research as work done under the auspices of the Frederick Cancer Research Center (FCRC), where Reuber worked, and that he did this personal research on company time. The district court in dismissing his claim held that venue did not lie in the District of Columbia for Reuber’s FTCA claim or his claims against the individual defendants, that in addition the court lacked personal jurisdiction over the individual defendants, and finally that Reuber’s allegations that Litton and Bionetics violated his constitutional rights were insufficient to confer subject matter jurisdiction. It further refused to exercise pendent jurisdiction over the common law claims against the corporate defendants.

We affirm the dismissal of the FTCA actions against the United States and the constitutional and common law tort claims [1044]*1044against the individual defendants generally for the reasons stated by the district court. We reverse the district court’s dismissal of constitutional and pendent state claims against the two corporate defendants, Litton Industries, Inc., and Litton Bionetics, Inc., and remand these claims to the district court.

I. Factual Background

A. Events Prior to 1981

From 1976 to April, 1981, Reuber, a Maryland resident, worked as a research pathologist at FCRC, a government-owned facility located in Maryland, which Bionetics operates pursuant to a cost-plus contract with the National Cancer Institute (NCI).2 Until 1981, Reuber’s employer, Bionetics, was apparently pleased with his work; as late as November, 1980, defendant Dr. Michael Hanna, Director of FCRC, rated Reuber’s job performance as outstanding, and earlier in 1981 Reuber was picked to head FCRC’s Experimental Pathology Laboratory. See Deposition of Michael George Hanna, Reuber v. United States, Civ. No. 81-1857 [hereinafter cited as Hanna Dep.].3

During this time FCRC encouraged Reuber to do personal research on his own time. Reuber contends that FCRC’s policy allowed researchers to take up to one day a week off from official work to engage in “scholarly activities,” see Deposition of Melvin D. Reuber at 196-99 [hereinafter cited as Reuber Dep.], which he interpreted to include personal research. Thus, Reuber conducted several studies based on review of NCI slides available at Tracor Jitco, a repository in Maryland for NCI slides. Id. at 29-80. He submitted several of these studies for publication without first clearing them through FCRC and NCI. Reuber also completed numerous FCRCsponsored studies, which he did subject to the FCRC and NCI clearance process prior to submittal for publication. Unlike his personal research, these studies were required to expressly state:

[t]he work upon which this publication is based was performed pursuant to [the FCRC] Contract ... with the [NCI].

Id., Exh. 4.4

In one personal study Reuber submitted for publication in 1979 dealing with the “carcinogenicity of malathion,” see Reuber v. United States, Civ. No. 81-1857, slip op. at 1 (D.D.C. Aug. 25, 1982) (Memorandum Opinion),5 he reported that after examining 24,000 slides used in prior NCI studies,6 he concluded contrary to the results of these studies that malathion did cause cancer in test mice and rats.

B. Events Leading to the Letter of Reprimand

In late 1980, Reuber’s malathion paper attracted publicity when the United States Department of Agriculture sought to conduct aerial spraying with malathion in California in an effort to eradicate the mediterranean fruit fly, which threatened the state’s agricultural industry. Upon request, Reuber sent a copy of his malathion study to Chris Jenkins, an employee of the John Muir Institute in Berkeley, California. Reuber put his office address at FCRC on the paper, which apparently led Jenkins and others at the John Muir Institute to [1045]*1045assume the work was sponsored and approved by FCRC and NCI. According to the government, this misconception was furthered by the John Muir Institute’s distribution of a packet which “cited Reuber’s study as that of FCRC/NCI.” Brief for Federal Appellees, No. 83-1536, at 4.

Following the distribution of Reuber’s paper, NCI officials began receiving a succession of telephone calls asking who Reuber was, and whether NCI still stood behind its conclusions in prior studies that malathion was not carcinogenic. See Brief for Appellee United States, No. 83-1536 at 8.7 In addition, a letter from a California official to NCI complaining about Reuber’s study was forwarded to defendants Adam-son and Hartwell, both officials at NCI.

Hartwell and Adamson began an investigation. Hartwell contacted Dr. James Liverman at Bionetics and alerted him to the controversy prompted by Reuber’s study. According to Reuber, Hartwell subsequently accused him of misusing government funds and misrepresenting himself as an NCI employee. See Brief for Appellant, No. 82-2376, at 14. Liverman relayed these allegations to defendant James Nance, President of Bionetics, who in turn notified FCRC Director Hanna of them.

At the same time, according to the government, Adamson checked with NCI pathologists and other scientists involved in the original malathion studies and concluded that their negative findings on the carcinogenicity of malathion were correct. See Brief for Federal Appellees, No. 83-1536, at 9. He contacted Hanna with this information.

The parties disagree about the events that ensued. According to the government, “Dr. Hanna took the matter over from there.” Brief for Federal Appellees, No. 83-1536, at 10. Hanna originally wanted to fire Reuber, but was convinced not to do so by defendant Dr. Vincent DeVita, the director of NCI and the person ultimately responsible for the review of Bionetics’ FCRC contract. Id. Hanna instead drafted a strong letter of reprimand, and despite suggestions by defendant Dr. William Payne, an NCI official, to “tone it down a bit,” sent it as originally drafted. Id.

According to Reuber’s version, on the other hand, Hanna was pressured into disciplining Reuber by NCI officials who were “very upset” by Reuber’s reinterpretation of the NCI [malathion] studies and his la-belling as carcinogenic chemicals that NCI had found to be noncarcinogenic. Brief for Appellant, No. 82-2376, at 17. Reuber alleges that Hartwell “went around the NCI telling people that this time he was ‘going to get’ plaintiff.” Id. He also claims that, although NCI generally does not make employment decisions regarding Bionetics’ employees at FCRC, Adamson instructed Hanna to call Reuber to “straighten ... out” matters, id., and “DeVita ... insisted” that Hanna write the letter of reprimand. Brief for Appellant, No. 83-1536, at 11.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Edley v. Berryhill
District of Columbia, 2019
Howe v. Embassy of Italy
68 F. Supp. 3d 26 (District of Columbia, 2014)
Turner v. Abbott
53 F. Supp. 3d 61 (District of Columbia, 2014)
Gardner v. Mabus
49 F. Supp. 3d 44 (District of Columbia, 2014)
Simon v. Republic of Hungary
37 F. Supp. 3d 381 (District of Columbia, 2014)
Ghaffari v. Wells Fargo Bank, N.A.
6 F. Supp. 3d 24 (District of Columbia, 2013)
Scott v. Conley
937 F. Supp. 2d 60 (District of Columbia, 2013)
Patel v. Phillips
933 F. Supp. 2d 153 (District of Columbia, 2013)
Coltrane v. Lappin
885 F. Supp. 2d 228 (District of Columbia, 2012)
Marshall v. I-Flow, LLC
856 F. Supp. 2d 104 (District of Columbia, 2012)
Wesby v. District of Columbia
841 F. Supp. 2d 20 (District of Columbia, 2012)
Rundquist v. VAPIANO SE
798 F. Supp. 2d 102 (District of Columbia, 2011)
Orellana v. CropLife International
740 F. Supp. 2d 33 (District of Columbia, 2010)
Lewy v. Southern Poverty Law Center, Inc.
723 F. Supp. 2d 116 (District of Columbia, 2010)
Exponential Biotherapies, Inc. v. Houthoff Buruma N.V.
638 F. Supp. 2d 1 (District of Columbia, 2009)
National Community Reinvestment Coalition v. NovaStar Financial, Inc.
631 F. Supp. 2d 1 (District of Columbia, 2009)
Sanchez Ex Rel. Rivera-Sanchez v. United States
600 F. Supp. 2d 19 (District of Columbia, 2009)
Elemary v. Philipp Holzmann A.G.
533 F. Supp. 2d 144 (District of Columbia, 2008)
Fletcher v. District of Columbia
481 F. Supp. 2d 156 (District of Columbia, 2007)
FC INVESTMENT GROUP LC v. Lichtenstein
441 F. Supp. 2d 3 (District of Columbia, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
750 F.2d 1039, 242 U.S. App. D.C. 370, Counsel Stack Legal Research, https://law.counselstack.com/opinion/melvin-d-reuber-v-united-states-of-america-two-cases-melvin-d-reuber-cadc-1985.